Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?-Reference-Cited by-同舟云学术

Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?

Published:2021-07-01 Issue:3 Volume:55 Page:174-181
ISSN:1336-0329
Container-title:Endocrine Regulations
language:en
Short-container-title:

Author:

Tomo Sojit¹,Banerjee Mithu¹,Sharma Praveen¹,Garg Mahendra²

Affiliation:

1. Department of Biochemistry , All India Institute of Medical Sciences , Jodhpur , India

2. Department of Medicine , All India Institute of Medical Sciences , Jodhpur , India

Abstract

Abstract The pathophysiology of COVID comprises an exaggerated pro-inflammatory response. Hypothalamic-pituitary-adrenal (HPA) axis has a crucial role in various inflammatory conditions and modulated immunological response. Limited evidence is available regarding the incidence and the effect of HPA dysfunction in COVID-19. Although the cortisol levels have only been estimated in a few studies, the dehydroepiandrosterone sulfate (DHEAS) release from the adrenal gland has not been explored yet. In this mini review, the authors discuss the role of dehydroepiandrosterone (DHEA) and DHEAS in the acute stress response and immunological modulation. Various effects of DHEAS have been demonstrated in different diseases. The specific inhibitory effect of DHEA on interleukin 6 (IL-6) could be of paramount importance in COVID-19. Further, DHEA supplementation has already been proposed in inflammatory conditions, like rheumatoid arthritis. DHEAS levels in COVID-19 may help to understand the HPA axis dysfunction as well as the possibility of repurposing DHEA as a drug for mitigating the pro-inflammatory COVID-19.

Publisher

Walter de Gruyter GmbH

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.sciendo.com/pdf/10.2478/enr-2021-0019

Reference74 articles.

1. Andus T, Straub RH, Vogl D et al. Low serum levels of dehydroepiandrosterone sulfate (DHEAS) in Crohn’s disease (CD) and ulcerative colitis (UC). Gastroenterology 110, A855, 1996.

2. Arlt W, Hammer F, Sanning P, Butcher SK, Lord JM, Allolio B, Annane D, Stewart PM. Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab 91, 2548–2554, 2006.

3. Arvat E, Di Vito L, Lanfranco F, Maccario M, Baffoni C, Rossetto R, Aimaretti G, Camanni F, Ghigo E. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: Dose-response study. J Clin Endocrinol Metab 85, 3141–3146, 2000.

4. Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H. A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells. Ann N Y Acad Sci 1110, 630–640, 2007.

5. Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C, Lord JM, Sayer AA. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age (Dordr) 35, 963–971, 2013.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sources and control of impurity during one-pot enzymatic production of dehydroepiandrosterone;Applied Microbiology and Biotechnology;2024-06-29

2. The impact of menopause and serum DHEA-S level on the severity of Covid-19;Maturitas;2024-01

3. The Possible Mechanisms of Cu and Zn in the Treatment and Prevention of HIV and COVID-19 Viral Infection;Biological Trace Element Research;2023-08-23

4. Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study;Pharmacological Reports;2023-08-16

5. Molecular Biomarker Identification Using a Network-Based Bioinformatics Approach That Links COVID-19 With Smoking;Bioinformatics and Biology Insights;2023-01